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Introduction
When considering the importance of thyroid function 
in pregnancy, it is also essential to consider iodine, 
which is an integral component of thyroid hormone. It 
has been long established that severe maternal iodine 
deficiency has a profound deleterious impact on offspring 
neurodevelopment (1). Infants or children with an 
intelligence quotient (IQ) of 40 or less, a condition known 
as “cretinism”, were commonly reported in severely iodine 
deficient areas worldwide; thanks to the introduction of 
iodine supplementation before and during early pregnancy, 
this condition can now be prevented (2).
In the last 20 years there has been a substantial increase 
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in our understanding of the importance of thyroid 
hormones for maintaining a successful pregnancy and foetal 
development, especially with regard to its neurological 
development (3-8). In particular, there has been a growing 
appreciation that maternal thyroid hormone levels are 
especially important in the first half of pregnancy whilst the 
foetal thyroid is developing. 
Thyroid disorders are common globally in women of 
child-bearing age (9); furthermore, pregnancy increases 
the demands on the hypothalamic-pituitary-thyroid axis. 
As a result thyroid dysfunction, particularly borderline 
thyroid abnormalities, are frequently encountered during 
pregnancy. Correction of both overt hypothyroidism and 
hyperthyroidism dramatically reduces the risk of adverse 
obstetric outcomes including foetal loss and preterm birth 
(3,6). Currently all endocrine, thyroid, and obstetrical 
societies recommend initiating treatment for overt thyroid 
disease detected in pregnancy. However, the benefits of 
treating more marginal thyroid function such as subclinical 
hypothyroidism (ScHypo) and isolated hypothyroxinemia 
(IH) are less clear, therefore the need of a universal 
screening program of thyroid function in pregnancy is still 
a major debate in thyroidology. Furthermore many women 
are established on levothyroxine either prior to or during 
pregnancy (10).
Thyroid physiology in pregnancy
Our understanding of the appreciable effects of pregnancy 
on thyroid economy has had notable advances in the 
last 20 years (4). Pregnancy determines an increase of 
urinary iodine excretion and thyroxine-binding globulin 
(TBG) levels, and a rise in thyroid hormone degradation 
by placental type III deiodinase; furthermore, the foetus 
utilizes maternal thyroid hormones. Thus the demands on 
maternal thyroid axis are increased, and as a consequence 
the maternal thyroid hormone production rises (3). This 
scenario induces compensatory mechanisms such as an 
increased thyroidal production of free-thyroxine (FT4) 
and free tri-iodothyronine (FT3) triggered by the placental 
secretion of human chorionic gonadotrophin (hCG) (11). 
Furthermore it is well known that pregnancy induces 
a condition of general immunosuppression for all its 
duration (12). As a consequence, the activity of autoimmune 
disorders is reduced during gestation, including thyroid 
autoimmunity and leading to additional changes in thyroid 
hormones levels.
Table 1 summarizes the significant, but reversible, 
changes in thyroid function occurring in pregnancy 
(3,5). During gestation, plasma volume and glomerular 
filtration rate increase significantly, with consequent 
augmented excretion of iodine in the urine (13). Thus the 
reduced serum iodine concentration exacerbates iodine 
deficiency, and may be causative of goitre and reduced 
levels of maternal thyroxine (T4), especially in areas of 
endemic cretinism (14). An augmented thyroid volume 
has been observed even in areas of mild-moderate iodine 
deficiency (15,16), but not in iodine sufficient regions (15). 
This is of particular relevance to the UK which is iodine 
deficient (17) and data from the UK has shown mild-
moderate iodine deficiency in pregnancy is associated 
with a lower child IQ (18). A daily iodine intake of 250 
µg in pregnancy is recommended by several different 
authorities (19,20), however it is not always achieved even 
in developed parts of the world (9,21). Endocrine disruptors 
may exacerbate iodine deficiency and may also have a 
Table 1 Physiologic changes in pregnancy that influence thyroid function
Physiologic change Impact on thyroid economy
↑Thyroid binding globulin (TBG) ↑Serum total T4 and T3 concentration
↑hCG levels (1st trimester) ↑Free T4 and ↓TSH (thyroidal hCG response may be impaired in TPOAb 
positive women)
↑Plasma volume ↑T4 and T3 pool size
↑Type III iodothyronine-deiodinase activity (inner ring 
deiodination) from placenta
↑T4 and T3 degradation consequent ↑demand on thyroid gland for increased 
hormone production
Thyroid gland enlargement (in some women) ↑Serum thyroglobulin
↑Renal iodine clearance ↑Iodine requirements; ↓hormone production in iodine deficient areas
Adapted from Lazarus (6). hCG, human chorionic gonadotrophin; TBG, thyroxine binding globulin; T3, triiodothyronine; T4, thyroxine. Up 
arrow (↑), increased; down arrow (↓), decreased.
Annals of Thyroid, 2018 Page 3 of 16
© Annals of Thyroid. All rights reserved. Ann Thyroid 2018aot.amegroups.com
deleterious effect on offspring neurodevelopment (22,23). 
Thus, to prevent foetal brain damage additional iodine 
supplementation in pregnancy may be required in areas 
of suboptimal iodine nutrition. Ideally iodine sufficiency 
should be attained prior to conception by either universal 
salt iodisation or targeting women of child-bearing age (24).
During pregnancy the levels of thyroid hormone 
transport proteins rise, especially TBG, due to oestrogen-
induced increase in TBG sialylation with consequent 
reduced degradation and increased half-life, as well as 
enhanced hepatic synthesis (25,26). As a consequence, total 
T4 and total T3 levels rise.
The hCG glycoprotein hormone shares a common 
alpha subunit with thyroid stimulating hormone (TSH) 
but has a unique beta subunit, which confers specificity; the 
amount and type of hCG secretion by placenta seems to 
be somewhat dependent on ethnicity (27). In vitro studies 
on thyroid tissue and on eukaryotic cells stably expressing 
the human TSH receptor (TSHR) showed that hCG acts 
as a TSH agonist (28); however others showed limitations 
of such in vitro assays, therefore this topic is still object of 
controversy (29).
The incidence of gestational transient hyperthyroxinemia 
caused by elevated hCG levels and therefore not treated was 
0.285% in a study screening more than 23,000 pregnant 
women (30). There is good evidence that hyperemesis 
gravidarum (severe nausea and vomiting), which sometimes 
requires hospitalisation for the management of its potential 
complications including dehydration and ketosis, may 
be associated with hyperthyroidism due to excess hCG 
stimulation (31). Furthermore, both the hCG secreted 
in the first trimester of pregnancy and that produced by 
hydatidiform mole tissue, have a high thyroid stimulating 
specific activity (32). The sensitivity of TSHR to hCG 
has also been demonstrated by a few isolated case reports 
of familial gestational hyperthyroidism caused by mutant 
TSHR (missense mutation) which was more sensitive to 
hCG than the wild type receptor (33-35). Recent data 
suggests that women with positive autoantibodies to thyroid 
peroxidase (TPOAb) may have an impaired response to 
hCG (36) and therefore may not be able meet the extra 
demands placed on the thyroid. This may be a key factor in 
why TPOAb positivity is associated with adverse outcomes.
In this complex scenario the precise mechanisms 
leading to a decline in free thyroid hormones have not 
been elucidated, however the interaction of oestrogens, 
hCG, TSH and thyroid binding proteins is crucial. 
In iodine deficient areas (including marginal iodine 
deficiency) the pregnant woman may become significantly 
hypothyroxinaemic with preferential T3 secretion, 
especially if iron deficient (37). As a general rule, FT4 
transiently rises in the first trimester due to the relatively 
high circulating hCG concentration, while FT4 decreases in 
the second and third trimester, albeit still within the normal 
reference range (3). Changes in FT3 concentration are also 
seen in which they broadly parallel the FT4, again within 
the normal range (3). The thyroidal ‘stress’ is also evidenced 
by a rise in the median TSH and serum thyroglobulin; in 
particular TSH levels have a specular trend compared with 
hCG, therefore lower in the first trimester and higher in 
the second and third trimesters (4,38). 
Thyroid function assessment during pregnancy
Clinical relevance
The profound changes that occur during pregnancy have 
consequences for thyroid hormone serum concentrations 
and the assessment of thyroid function. There is a 
significant overlap between the signs and symptoms of the 
hypermetabolic state typical of normal euthyroid pregnant 
women, and those due to thyroid dysfunction. Therefore, 
a differential diagnosis can be challenging to make, and 
the availability of reliable accurate tests for gestational 
thyroid function is crucial to this purpose. However, the 
notable underlying physiological changes occurring during 
pregnancy also cause many difficulties with the laboratory 
measurements of thyroid function. The diagnosis of 
maternal gestational thyroid dysfunction is of clinical 
importance for both maternal and foetal health (39,40), and 
therefore requires (I) specialised assays measuring thyroid 
hormones with high specificity and sensitivity; (II) normal 
and reliable intervals for comparison during pregnancy; 
and (III) appropriate treatment regimen. To this purpose 
dedicated guidelines have been published by several 
organizations (41,42).
Several factors influence thyroid status in pregnancy, 
including iodine status (16), hCG levels (11), ethnicity 
(27,43), body mass index (44), parity (44) and male foetal 
sex (44). A population of pregnant women not biased 
by such key factors is required to calculate more precise 
gestational-related reference ranges for thyroid hormones, 
essential to make a correct diagnosis. Therefore, centres 
should assess their normal thyroid reference-range 
excluding women with thyroid dysfunction and/or 
positivity for TPOAb, using medications altering thyroid 
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function, resident in areas of iodine deficiency. Equally, 
women who have undergone in vitro fertilization or are 
expecting twins, since both conditions are characterised by 
higher hCG levels (45). The current American Thyroid 
Association guidelines recommend the use of pregnancy 
specific, local population-based reference ranges where 
possible (46). Furthermore, normal thyroid status changes 
over pregnancy, therefore the accurate assessment of thyroid 
function in pregnant women requires the use of different 
gestational age (trimester-specific) reference intervals (47).
Two guidelines provided by the Endocrine Society (42) 
and the National Academy of Clinical Biochemistry (41) 
detailed the strengths and limitations of currently available 
thyroid function tests. TSH has been traditionally the 
primary marker of thyroid status during pregnancy, however 
the measurement of T4 levels is essential in differentiating 
between overt and subclinical thyroid disease, and the 
assessment of thyroid hormones during pregnancy has 
several weaknesses. In particular the free hormone assays 
based on measuring the concentrations of thyroid hormone 
binding-proteins are known to be method-dependent, and 
therefore are at risk of providing inaccurate FT4 and FT3 
values during gestation. Direct FT4/FT3 assays based on 
equilibrium dialysis are more reliable however less available 
since expensive and time-consuming (48). Finally, most 
laboratories still do not use pregnancy-specific reference 
intervals for thyroid function tests.
In some cases, serum TPOAb and autoantibodies 
to thyroglobulin (TgAb) and/or to TSHR (TRAb) can 
provide other information. TPOAb can predict the risk 
of hypothyroidism; low TSH levels in pregnant women 
are accompanied by TRAb in 60–70% of the cases, and 
need to be monitored since may cause foetal and neonatal 
hyperthyroidism (46).
TSH measurement
Since TSH and FT4 are linked by a log-linear relationship, 
very small changes in T4 levels will determine a much larger 
variation in serum TSH concentrations (49,50). For this 
reason serum TSH levels represent the first biochemical 
indicator checked in the suspect of thyroid dysfunction. 
However during gestation thyroid and pituitary functions 
undergo notable variations; for example during early 
pregnancy the significant rise in hCG concentrations 
determines a suppression of TSH levels by 20–50% by week 
10 (51). Therefore, the measurement of only serum TSH 
in women treated for thyroid dysfunction during gestation 
has several limitations since can result in maternal under-
replacement with levothyroxine, or overtreatment with 
anti-thyroid drugs (ATD), both scenarios causing maternal 
hypothyroidism with consequent increased risk for impaired 
foetal brain development. The biochemical evaluation of 
the hypermetabolic symptoms presented by women with 
reduced TSH but still normal FT4 levels may include the 
measurement of FT3 and FT3 index (FT3I). 
Total and free thyroid hormone measurements
T4 and T3 circulates >99% bound to plasma transport 
proteins, mainly to TBG and to a lesser extent to 
transthyretin and albumin; the free- and protein-bound 
hormones are at equilibrium (52). The highly concentrated 
(nanomolar) protein-bound hormone fractions act as a 
storage reservoir and prevent thyroid hormones from 
entering cells where they exert their biological effects. 
The biologically active form of thyroid hormones is that 
free from protein-binding, and present at much lower 
concentrations (picomolar) (53).
Assays for total thyroid hormones have been much easier 
to develop compared with their free component, due to 
their increased serum concentrations, and are considered 
more accurate and valid compared with free hormone 
assays. In particular total T4 assays generally agree quite 
well, and are characterised by better defined reference 
intervals in adults (54). However, in pregnancy oestrogens 
cause an increase of TBG levels and therefore a consequent 
increase of total T4 concentrations (up to 1.5-fold in the 
second trimester), thus gestation-specific reference intervals 
for total thyroid hormones are necessary for accuracy (6). 
Due to the influence of thyroid hormone binding proteins, 
in most clinical laboratories FT4 assays have replaced the 
total T4 testing.
The measurement of the free quote of thyroid hormones 
allows taking into account the biologically active form 
only, and this is a clear advantage. However, this approach 
has significant challenges compared with the total thyroid 
hormone assays due to: (I) the lower concentration of 
analyte; (II) the risk to disturb the equilibrium between the 
free and protein-bound hormone quotes; (III) the potential 
interference of the much higher concentrations of the 
protein-bound hormone quote. In fact due to the changes 
in the TBG concentrations during pregnancy, concern has 
been raised regarding the accuracy of FT4 assays (54). It 
has to be noted that such interference is maximum in the 
third trimester, while minimal in the first trimester, which 
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is the most important time-point for thyroid dysfunction 
screening. Furthermore, variation in FT4 as opposed to T4 
levels is more robustly associated with adverse obstetric and 
offspring outcomes (55,56). 
The first step in the measurement of the free hormones 
is their physical separation from the protein bound 
hormones by specific techniques (i.e., equilibrium dialysis 
or ultrafiltration), followed by immunoassay, or more 
recently using isotope dilution mass spectrometry (MS) 
(57-59). The immunoassay methodologies are more prone 
to interference by thyroxine binding protein abnormalities 
or immunoglobulins (i.e., heterophilic antibodies and 
antibodies to thyroid hormones) (60-62). Possible strategies 
to overcome this limitation are: (I) to measure the total 
hormone concentrations (T3 and T4) correcting for the 
increased binding proteins, i.e., directly measuring the 
TBG levels to provide T4/TBG or T3/TBG ratios; (II) 
to perform a T3 or T4 uptake test to estimate free thyroid 
hormone indices (63-67).
More recently free thyroid hormones have been 
measured by tandem MS which provides more accurate, 
specific, fast and simple measurements (68-70). Further 
development was achieved coupling MS with high 
performance liquid chromatography (62).
These assays are complex and laborious, therefore often 
not routinely employed in clinical practice and limited to 
specialized laboratories. In fact, clinical laboratories prefer 
to use commercially available immunoassays for FT4 and 
FT3 only estimating the concentration of the free thyroid 
hormone quote, since not physical separating that from 
the protein-bound hormone quote (71). Surprisingly, 
one of the commercially available FT4 assays resulted 
to correlate more closely to total T4 assays than to FT4 
measured following physical separation of the free-quote 
from binding proteins (72). However the physiological 
increase in TBG levels occurring during gestation has been 
showed to influence at various extents the results obtained 
with commercial FT4 immunoassays (73). This explains 
why a significant method-dependent variation exists when 
measuring gestational FT4 levels, with different groups 
reporting serum concentration of thyroid hormones to 
be decreased, increased or unchanged during pregnancy 
depending on the assays used; thus it is challenging 
to establish universal gestation-related FT4 reference 
intervals (60,61).
Considering the differences in thyroid hormones related 
to the laboratory method used and the gestation period, the 
use of method- and gestation-specific reference intervals 
is recommended for the correct interpretation of thyroid 
function in pregnant women (71). Method- and gestation-
specific reference intervals for FT4 should be derived in the 
appropriate reference populations. To this purpose both the 
iodine and thyroid autoimmunity status should be evaluated 
when selecting the reference population; only iodine 
sufficient subjects should be taken into account (41,42). 
Unfortunately, very few FT4 immunoassay manufacturers 
include appropriate method-specific normal pregnancy-
related reference intervals, and most clinical laboratory 
reports only provide reference intervals not adjusted 
for gestation, making challenging the interpretation of 
laboratory results during pregnancy. In cases where a clear 
diagnosis is difficult to reach, the integration of both free 
and total thyroid hormone assays, and/or reanalysis of the 
samples on a different platform are possible options to 
consider.
Trimester- and method-specific reference intervals
In order to reduce the global variability of thyroid hormone 
assessments, numerous trimester-specific population-
based reference intervals have been derived. In 2010 
Lazarus et al. provided a comprehensive summary of some 
trimester-specific reference ranges for different populations 
worldwide (5). In 2017 Korevaar et al. reported additional 
updated worldwide reference ranges for early pregnancy in 
their supplementary Table S1 (8).
Current T4 and TSH levels are affected worldwide by 
iodine deficiency, ranging from mild to moderate and still 
present in some geographical areas despite the national 
policies of iodine implementation using mandatory 
iodized salt. Furthermore, the overall iodine intake may be 
significantly different due to the variable content of natural 
iodine within the local food and water, or the presence of 
variable individual responses to supplementation (5). In 
the first trimester we assist to an increase of total thyroid 
hormone concentration, with consequent decrease of both 
FT4 and TSH. In areas of iodine sufficiency the second and 
third trimesters are characterised by increased TSH levels, 
while FT4 and FT3 levels decrease; this is not the case in 
iodine deficient populations due to the TSH stimulation (5). 
As previously highlighted the interpretation of gestational 
FT4 values needs caution to avoid misinterpretation, since 
the results of FT4 laboratory assays are characterised by 
significant variability even within the same population (60,61). 
It should be noted that the measurements by different 
methods in distinct populations did provide very dissimilar 
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ranges; furthermore slightly divergent results were 
produced even in the same population in case of different 
ethnicities, and the same method applied to different 
populations provided significantly different results (5). As 
additional point, the population-based reference ranges did 
not take into account the various genetic set-points specific 
for every subject (74,75). Similarly, gestational specific 
reference intervals may be more affected by intra-individual 
changes than specific single measurements. In fact the use of 
gestation- and method-specific reference intervals, even if 
determining a crucial reduction in results variability and risk 
of misinterpretation, should not prevent from considering 
also the intra-individual variability (5). 
In conclusion, a correct interpretation and comparison 
of gestation-specific results should always consider the assay 
analysis methods used, the size of the group evaluated, the 
subject inclusion and exclusion criteria including the iodine, 
ethnicity, age and singleton pregnancy status, the study 
design (cross-sectional or longitudinal) and the statistical 
methods used for data analysis. 
Epidemiology of thyroid disease in pregnancy
Overt maternal hypothyroidism—elevated TSH and low 
maternal FT4 concentrations—occurs in approximately 
0.2–0.6% of pregnant women (76,77), whereas ScHypo—
elevated TSH and normal FT4 concentrations—can occur 
in up to 18% of pregnancies depending on the precise 
definition and TSH cut-point used (8,46). IH is defined 
as a normal TSH with FT4 below the 2.5 percentile, 
and was originally considered to be a pregnancy specific 
condition possibly arising as a consequence of mild iodine 
deficiency. This concept has been more recently challenged 
as it occurs in iodine sufficient areas and does not typically 
resolve with iodine supplementation (78,79). Other factors 
including elevated BMI, older age, iron status and placental 
angiogenic factors have all been identified as likely risk 
factors for IH (80-82).
Pathological overt hyperthyroidism, usually due to 
Graves’ disease, occurs with a frequency of approximately 
0.2% (83), however previously treated maternal Graves’ 
disease prior to pregnancy is more common and can 
occur prior to 1% of pregnancies (83). New onset 
pathological hyperthyroidism during pregnancy is much 
rarer with a prevalence of 0.05% for Graves’ disease (83). 
Gestational thyrotoxicosis (suppressed TSH and elevated 
FT4) mainly through excess hCG and usually associated 
with hyperemesis gravidarum, occurs in up to 3% of 
pregnancies (83). Subclinical hyperthyroidism (ScHyper) 
most commonly occurs as a result of peak hCG levels (44) 
although may occur due to pathological thyroid disease. 
Owing to this dual cause of ScHyper its true consequences 
and prevalence are poorly studied. 
Consequences of maternal thyroid dysfunction
There is good evidence that maternal thyroid dysfunction 
during pregnancy may affect the obstetric outcome, as well 
as maternal and foetal health (4,6,8,39,40).
Table 2 summarises the impact of maternal thyroid 
hormones on foetal brain during different stages of 
pregnancy (5,84).
Overt hypothyroidism
Overt hypothyroidism has been repeatedly associated 
with a higher risk of adverse obstetric outcomes including 
foetal loss, premature delivery, low birth weight and 
preeclampsia (76,85). Effects have been observed on foetal 
neurodevelopment; a large case-control study demonstrated 
children born to women with untreated hypothyroidism 
had a 7-point lower IQ than women with normal thyroid 
function (86). 
ScHypo
ScHypo is also associated with similar adverse obstetric 
Table 2 Physiology of thyroid hormone availability to foetal brain
(A) Before onset of foetal thyroid function (1st trimester)
T4 and T3 are present in embryonic and foetal fluids and tissues
T4 and T3 are of maternal origin
Nuclear receptors are present and occupied by T3
D2 and D3 are expressed in brain
(B) Between onset of foetal thyroid function and birth  
(2nd–3rd trimesters)
Maternal transfer of T4 and T3 continues
Brain T3 is dependent on T4 and D2 and not on systemic T3
Normal maternal T4 protects foetal brain from T3 deficiency
Normal T3 in low T4 mother does not prevent cerebral T3 
deficiency
Adapted f rom Lazarus et  a l .  (5 ) .  D2,  iodothyronine-
deiodinase type II; D3, iodothyronine-deiodinase type III; T3, 
triiodothyronine; T4, thyroxine.
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outcomes as overt hypothyroidism, albeit with a more 
modest effect. Studies have demonstrated an increased 
incidence of adverse pregnancy outcomes including 
preterm delivery, placental abruption, respiratory distress, 
early pregnancy loss and admissions to the intensive care 
unit (87-91) but it has not been associated with impaired 
development of offspring (92-94).
IH
Although IH is also regarded as a mild form of thyroid 
failure, it has been found to be associated with impaired 
offspring developmental outcomes (7), but not obstetric 
outcomes in stark contrast to ScHypo. In particular, adverse 
consequences have been observed regarding offspring verbal 
delay (95). The relationship between maternal FT4 and 
offspring IQ appears to be “U” shaped with individuals with 
hypothyroxinemia having lower IQ, and lower grey matter 
and cortical volume (7). Maternal IH has also been shown 
to be associated with offspring autism (96) and attention-
deficit/hyperactivity disorder (ADHD) (97,98).
TPOAb positivity
TPOAb positivity is a major risk factor for ScHypo (99). 
However, the combination of ScHypo and TPOAb 
positivity appears to have a synergistically adverse outcome. 
In particular, adverse synergistic associations occur for 
miscarriage, premature delivery and gestational diabetes 
mellitus (100). It also appears to be a risk factor in its own 
right for miscarriage and pre-term delivery (101). 
Pathological hyperthyroidism
Pathological hyperthyroidism is a condition independent 
from hCG levels, and usually determined by Graves’ disease 
or, more rarely, by an autonomous production of thyroid 
hormones (i.e., toxic goitre or adenoma). It is associated 
with increased risk of maternal heart failure, preeclampsia, 
foetal loss, pre-term birth and low birth weight (83,102,103).
Given that all endocrine and obstetric guidelines endorse 
the treatment of pathological thyroid dysfunction, it is 
difficult to ascertain from current studies which of these 
negative outcomes are secondary to the maternal thyroid 
dysfunction itself, or foetal hyperthyroidism (due to TRAb 
crossing the placenta), or consequences of treating the 
maternal thyrotoxicosis, including ATD side effects or 
induced foetal hypothyroidism (8). 
Gestational hyperthyroidism and ScHyper
Gestational hyperthyroidism is a usually transient condition 
caused by increased hCG levels during the first trimester 
of pregnancy, determining an augmentation of thyroid 
hormone production. It is usually responsible for the 
majority of ScHyper cases diagnosed in pregnancy and is 
considered to be a non-pathological condition (8). 
There is a current lack of data investigating the effects 
of pathological ScHyper on adverse pregnancy, maternal, 
foetal and neonatal outcomes; one first difficulty is to 
reliably distinguish cases of pathological versus non-
pathological (gestational) ScHyper (8). This step is 
crucial, since recent findings showed that increased levels 
of thyroid hormones did not represent a risk factor for 
preeclampsia if associated with high hCG levels (indicating 
gestational hyperthyroidism), while a 3.4–11.1-fold higher 
risk of such adverse outcome was present if they were 
associated with low hCG levels (indicating pathological 
hyperthyroidism) (104). A combined measurement 
of thyroid function and hCG would therefore help in 
distinguishing these two forms of ScHyper in pregnancy.
Benefits of treatment of maternal thyroid 
dysfunction
Treatment of overt hypothyroidism
Although no randomised controlled trials of levothyroxine 
for overt hypothyroidism in pregnancy have been 
conducted, the wealth of data regarding the adverse 
consequences of overt hypothyroidism with pregnancy 
effects mean performing such studies would be unethical. 
However, all endocrine and obstetric society guidelines 
recommend treatment of overt hypothyroidism in 
pregnancy; in women established on levothyroxine prior to 
pregnancy dose adjustments are often needed to cope with 
the increased thyroidal demand (8,46). 
Despite this, many women on levothyroxine have sub-
optimal thyroid function during pregnancy and in those with 
TSH levels >4.5 mU/L an increased risk of foetal loss has 
been described (105). The “U” shaped response seen with 
maternal thyroid function and IQ (7) and the CATS II study 
(94,106) also shows that caution should be taken in not over-
treating patients with hypothyroidism or ScHypo. This is 
particularly important in treating women with milder thyroid 
abnormalities as the residual function in the thyroid gland 
may be readily responsive to hCG resulting in over-treatment 
if injudicious doses of levothyroxine are given. 
Annals of Thyroid, 2018Page 8 of 16
© Annals of Thyroid. All rights reserved. Ann Thyroid 2018aot.amegroups.com
Box 1 reports a clinical algorithm for the correct 
management of hypothyroidism in pregnancy (8,42). 
Treatment of ScHypo and IH
To date three large randomized controlled trials have 
investigated the effects of screening and treating borderline 
low thyroid function in pregnancy: the controlled antenatal 
thyroid screening (CATS) study (92), a study by Casey 
et al. (93), and a recent study by Nazarpour et al. (107), 
summarized in Table 3. 
In terms of offspring benefits, neither CATS nor Casey 
study showed any beneficial effects of treatment on children 
IQ. Reasons for negative findings might include relatively 
late initiation of treatment (particularly in the Casey 
study) (93) and early age of IQ assessment (particularly in 
the CATS study) (92). Follow on analysis of the CATS study 
(CATS II) confirmed no apparent benefit of treatment at 
age 9 (94) although identified levothyroxine over-treatment 
may increase the risk of ADHD (106). 
In terms of pregnancy outcomes, no benefit was observed 
with levothyroxine on obstetric outcomes in both the 
Casey (93) and the Nazarpour study (107), as well as 
in a meta-analysis of the two studies considering five 
obstetrical and neonatal outcomes: preterm delivery 
<37 weeks gestation, gestational age at delivery, placental 
abruption, neonatal intensive care admission and head 
circumference (108). A more recent analysis using data 
linkage and the majority of the CATS cohort identified that 
levothyroxine treatment significantly reduced the risk of 
miscarriage/still birth (109). This was in agreement with 
previous findings from another prospective study identifying 
that levothyroxine reduced the risk of miscarriage and pre-
term birth (110). 
Treatment of pathological hyperthyroidism
The treatment of hyperthyroidism in pregnancy is 
imperative due to its important negative effects on 
pregnancy outcome and both mother and foetus health 
(83,102,103). Thus no randomized controlled trials 
have been conducted in pregnant hyperthyroid women 
comparing ATD interventions with no interventions (111).
ATD are the preferred treatment during pregnancy 
(46,112) since radioiodine is absolutely contra-indicated 
due to deleterious effects on foetal thyroid gland and 
teratogenicity (113-115), and thyroidectomy in pregnancy 
results in increased morbidity compared to non-pregnant 
women (116). Thyroidectomy can be considered in 
special circumstances during pregnancy, such as allergy/
contraindications to ATD or if euthyroidism cannot be 
achieved despite high doses. Thyroidectomy if required 
should be performed in the second trimester.
All ATD cross the placenta and therefore the lowest 
possible dose to control hyperthyroidism is recommended 
(46,76). The most used ATD are carbimazole (CBZ)/
methimazole (MMI) and propylthiouracil (PTU), and it 
is still unclear whether there is a substantial difference in 
Box 1 Management of hypothyroidism in pregnancy
Preconception: optimize levothyroxine therapy in patients with pre-existing disease, warning them of the need to increase dose over 
pregnancy and the need for closer monitoring
On confirmation of pregnancy, increase dose by 30–50% of preconception dose. Dose requirement is often higher in post-ablative and 
post-surgical hypothyroidism
If newly diagnosed overt hypothyroidism in pregnancy, start pregnancy-specific body weight-based dose: 2 mcg/kg/day
Be aware of drug interactions:
(I) Drugs which impair thyroxine absorption: iron supplements, cholestyramine, calcium carbonate, soy milk
(II) Drugs which increase thyroxine clearance: carbamazepine, rifampicin, valproate
Check thyroid function early in first trimester and every 4–6 weeks 
Aim for TSH <2.5 mU/L in the first trimester and <3 mU/L in later pregnancy. Take care to avoid a T4 level that is too high—aim for upper 
half of the reference-range
After delivery reduce levothyroxine to preconception dose
Recheck thyroid function at 6 weeks postpartum
Adapted from Lazarus (6).
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placental transfer between them; the choice of ATD used 
is therefore based on side effects. CBZ/MMI have been 
considered for years to be associated with an increased 
risk of embryopathy than PTU (113). Thus considering 
that the teratogenic risk is greater in early pregnancy, and 
that PTU is associated with increased risk of maternal 
hepatotoxicity (117), guidelines advise to use PTU in the 
first trimester, and then switch to CBZ/MMI (42,118). 
However more recent evidence suggests a similar rate of 
malformations occurring with both CBZ/MMI and PTU, 
even if slightly lower with PTU, and no benefits derived 
from switching from CBZ/MMI to PTU during the first 
trimester (119). These observations therefore question 
the clinical utility of drug switch in early pregnancy, and 
underline the necessity to identify new ATD drugs with 
reduced or absent side effects.
To reduce unnecessary exposure to ATD in early 
pregnancy ideally all potentially fertile women should be 
given written instructions to (I) perform a pregnancy test 
within a few days after the 1st day of a missed (or atypical 
week) menstrual period, if pregnancy is a possibility; (II) if 
the pregnancy test is positive promptly contact physician/
specialist nurse and do not take further ATD until advice 
given. Considering the risks of hyperthyroidism on one 
side, and those derived from ATD interventions to the 
other, some authors suggest that fertile women affected 
with hyperthyroidism and seeking pregnancy should plan 
thyroid surgery or radioactive iodine before the plan to 
become pregnant (111,118). 
TRAb can cross the placenta especially during the second 
half of pregnancy, therefore can trigger foetal and neonatal 
hyperthyroidism, with deleterious consequences including 
but not limited to intrauterine growth retardation, 
craniosynostosis and death (120). Thus, women affected 
with Graves’ disease (both current and past) and women 
previously treated by either thyroid surgery or radioiodine 
should have their serum TRAb levels measured early in 
pregnancy to mitigate foetal and neonatal morbidity and 
mortality (46). If positive, and especially if elevated, TRAb 
should be measured again at weeks 18–22 and in the 
last trimester (30–34 weeks); if still positive, appropriate 
neonatal and postnatal monitoring should be performed, 
and ATD treatment given if necessary.
The management of pathological hyperthyroidism 
secondary to Graves’ disease is summarized in Box 2.
Treatment of transient gestational thyrotoxicosis and 
ScHyper
Transient gestational thyrotoxicosis usually occurs during 
the first trimester of pregnancy, and spontaneously resolves 
when hCG levels decrease, therefore ATD interventions 
are not indicated, while beta-blockers may be considered in 
symptomatic cases (111,121). Similarly, no ATD treatment 
is required for women with hyperemesis gravidarum; 
however, they need careful electrolyte monitoring and may 
Table 3 Summary of the CATS, Casey and Nazarpour studies 
CATS study [2012] Casey study [2017] Nazarpour study [2018]
Countries UK, Italy USA Iran
Placebo-controlled No Yes No
N randomised 794 677 366
Maternal age (y: mean ± SD) 30±5.4; controls 31±5.3 27.7±5.7; controls 27.3±5.7 27.0±5.3; controls 26.9±4.7
Gestational age at recruitment 
(weeks)
[median (IQR)]*, 12.3 (11.6–13.6); 
controls 12.3 (11.6–13.5)
(mean ± SD)#, 16.6±3.0; controls 
16.7±3.0
(mean ± SD)^, 11.4±4.1; 
controls 12.2±4.3
Baseline TSH (mU/L) (median) UK 3.8 (IQR 1.5–4.7); controls 3.2 
(IQR 1.2–4.2). Italy 3.1 (IQR 1.3–4.0); 
controls 2.4 (IQR 1.3–3.9)
4.5 (95% CI, 4.4–4.7); controls 4.3 (95% 
CI, 4.2–4.5)
3.8 (IQR 2.8–4.8); controls 
3.6 (IQR 3.1–4.2)
Clinical outcomes Offspring IQ (age 3 y) Pregnancy outcomes; offspring IQ (age 
5 y); offspring behaviour (age 3–5 y); 
offspring Bayley-III score (age 1–2 y); 
offspring DAS-II score (age 3 y)
Pregnancy outcomes
*, at screening; #, at randomisation; ^, at first visit. y, years; DAS, differential ability score; IQR, interquartile range; SD, standard deviation; 
95% CI, 95% confidence interval. 
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require intravenous fluids, especially in severe forms.
ScHyper during pregnancy is usually determined 
by transient gestational thyrotoxicosis, therefore non-
pathological and not requiring ATD treatment. Due to 
the difficulty to distinguish between pathological and 
gestational ScHyper, so far, no studies have investigated 
and compared the benefits, as well as the potential arms due 
to the drugs’ side effects, of treating pathological ScHyper 
with ATD (8). Even a mild increase of maternal FT4 
levels during pregnancy was found to be associated with 
preeclampsia (104), reduced birth weight (8), reduced child 
neurocognition (7) and increased ADHD disorder (106), 
however it is unlikely that the benefits of ATD treatment 
would overcome its risks (8).
The consequences of thyroid disease and benefits of 
treatment are summarized in Table 4.
Universal thyroid screening in pregnancy
Universal thyroid screening in pregnancy is a key debate 
in thyroidology. As we have indicated thyroid dysfunction 
is common in pregnancy and has substantial adverse 
implications. Furthermore, it is readily detectable and can 
be inexpensively treated. However, as subclinical thyroid 
disease and IH represent the vast majority of the thyroid 
abnormalities, and the benefits of treatment here are less 
clear, screening is therefore contentious. Nevertheless 
universal thyroid screening in pregnancy appears to be very 
cost-effective; screening solely for overt hypothyroidism 
also had a cost-effectiveness ratio of $6,776/QALY (quality 
adjusted life-year) (122) which is favourable compared to 
gestational diabetes mellitus screening ($12,078/QALY) and 
is well below the $50,000/QALY figure used in the United 
Table 4 Summary of consequences of abnormal thyroid function and potential treatment benefits
Thyroid
dysfunction
Obstetric outcomes Offspring neurological development
Effect Impact of treatment Comment Effect Impact of treatment Comment
Overt hypothyroidism −− ++ −− ++
Subclinical
hypothyroidism
− ? Data for benefit are mixed. 
May require relatively early 
treatment for clear benefit
? ? No apparent benefit
Isolated 
hypothyroxinemia
? ? Lack of studies − ? Unclear benefit
Overt pathological 
hyperthyroidism




? ? Lack of studies ? ? Lack of studies
−, moderately adverse; −−, strongly adverse; +, moderately beneficial; ++, strongly beneficial; question mark (?), unclear. 
Box 2 Management of Graves’ hyperthyroidism in pregnancy
Discuss with patient the need for ATD treatment, including advice on the effect on the patient, foetus and implications for breastfeeding
Ideally use propylthiouracil for the first trimester; consider stopping ATD if possible at this stage, or switching to carbimazole/methimazole 
although some clinicians choose to continue propylthiouracil
Monitor thyroid function regularly throughout gestation (4–6 weeks), adjusting ATD dose if necessary
Render patient euthyroid up to and during labour
Serial ultrasonography of the foetus
Check TRAbs at 30–34 weeks and inform pediatrician if TRAb positive
Check infant for thyroid dysfunction if indicated
Review postpartum—check for exacerbation and advise about breastfeeding if still on ATD
Adapted from Lazarus (6). ATD, anti-thyroid drugs; TRAb, TSHR antibody.
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States as a criteria for screening decisions.
Taken together, it is widely accepted that thyroid 
dysfunction is an important health problem especially in 
pregnancy (123). Accepted, effective and well-established 
treatments are available, as is the ability to readily and easily 
make a diagnosis. Furthermore, thyroid function testing 
is universally suitable to patients. For hypothyroidism, 
but to a lesser extent hyperthyroidism, there is a well-
recognised asymptomatic stage. The natural history of 
subclinical thyroid dysfunction leading to overt disease 
is well understood, although many women with ScHypo 
will not progress to overt hypothyroidism if left untreated. 
Universal thyroid screening is cost effective even if only 
overt thyroid disease is considered and the nature of 
screening in pregnancy ensures it will be a continuous 
process. Thus universal thyroid screening in pregnancy 
meets almost all the criterion laid out by Wilson and 
Jungner (124). A key criterion is not resolved as there is not 
an agreed policy on whom to treat given the debate regarding 
management and treatment thresholds of IH and subclinical 
thyroid dysfunction. This can only be resolved by further 
appropriately powered randomised controlled trials.
Conclusions
In the last decade in particular, our knowledge regarding 
the diagnosis and treatment of thyroid disease in pregnancy 
has been revolutionised by substantial advances. In 
particular we reached a better understanding of the thyroid 
hormone physiology during pregnancy and the gestational-
derived stress on the thyroid, which is exacerbated in areas 
of iodine deficiency. Furthermore, new developments have 
been achieved in the technology for thyroid hormone 
analysis, and progress has been made in defining pregnancy-
specific reference intervals for thyroid hormones. In fact, 
the variation in assay methodology, and other determinants 
of thyroid function, indicated the necessity of establishing 
normative gestational-related (trimester-specific) reference 
ranges for thyroid hormones which are locally derived, 
namely method- and instrument-specific for the particular 
laboratory where samples were tested, and generated in 
iodine sufficient populations excluding women positive for 
TPOAb. This is crucial to prevent misinterpretation of 
thyroid function test results during pregnancy.
There is growing evidence that TPOAb positivity and 
higher TSH levels synergistically interact to increase 
the risk of adverse pregnancy outcomes. Even modest 
abnormalities in FT4 levels as seen in IH are also associated 
with adverse neurological development in offspring 
further supporting the role of thyroid hormone in foetal 
neurodevelopment. These findings would support the use 
of thyroid screening in pregnancy, although more data are 
needed.
Hypothyroidism is common in pregnancy and should 
be appropriately treated to reduce obstetric and foetal 
complications. Given foetal brain development requires 
adequate thyroxine delivery to foetal neurones, it also 
seems reasonable to treat mothers with hypothyroidism 
with levothyroxine to prevent IQ decrement as well as for 
obstetric reasons. Women already receiving levothyroxine 
require an increase in dose during gestation aiming for the 
top of the FT4 reference-range, however caution is needed 
to avoid over-treatment and potentially modest deleterious 
effects on behaviour.
Hyperthyroidism in pregnancy, usually due to Graves’ 
disease, is uncommon but has deleterious effects on 
mother and foetus and requires therapy. Especially in 
early pregnancy treatment with ATD may increase the risk 
of foetal abnormalities, although treatment is safer than 
uncontrolled thyrotoxicosis. Use of the lowest dose of ATD 
possible, including consideration of temporary cessation 
of treatment during critical periods of organogenesis 
with close monitoring, will mitigate this risk. Subclinical 
and mild forms of hyperthyroidism are usually caused by 
gestational thyrotoxicosis, a non-pathological condition 
usually self-limiting and not requiring treatment with ATD.
Further prospective trials of early  screening of 
thyroid function in pregnancy with both obstetric and 
developmental outcomes are still required to clarify whether 
universal thyroid screening in pregnancy is necessary. In the 
meantime, the correction of worldwide iodine deficiency 
continues to be required and monitored, and the impact of 
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